| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Common Stock | Award | +5.66K | 5.66K | Oct 5, 2021 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Stock Option (Right to Buy) | Award | +25.2K | 25.2K | Oct 5, 2021 | Common Stock | 25.2K | $12.50 | Direct | F2, F3 | |||
| transaction | XERS | Stock Option (Right to Buy) | Award | +20K | 20K | Oct 5, 2021 | Common Stock | 20K | $10.00 | Direct | F2, F3 | |||
| transaction | XERS | Stock Option (Right to Buy) | Award | +11.2K | 11.2K | Oct 5, 2021 | Common Stock | 11.2K | $4.68 | Direct | F2, F3 | |||
| transaction | XERS | Stock Option (Right to Buy) | Award | +11.2K | 11.2K | Oct 5, 2021 | Common Stock | 11.2K | $3.90 | Direct | F2, F4 |
| Id | Content |
|---|---|
| F1 | On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. |
| F2 | At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. |
| F3 | These options are fully vested as of the date hereof. |
| F4 | Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders. |